Optimizing Antiplatelet Therapy in Cardiogenic Shock

Program Description

Dr. Gregory Serrao from Mount Sinai discusses antiplatelet concerns and pharmacodynamics in the context of cardiogenic shock. Next, review the trial data, indications, and contraindications on cangrelor presented by Dr. Jennifer Rymer, MD, from Duke Health. Furthermore, you will understand the optimal “recipe” for antiplatelet management in HR NSTEMI, STEMI, and cardiogenic shock. Finally, view a case focused on antiplatelet therapy with cardiogenic shock.

Educational Objectives

Upon completion, participants should be able to:

• Examine the pharmacokinetic/pharmacodynamic profile of parenteral antiplatelet agents
• Review current data on antiplatelet considerations in acute coronary syndrome (ACS) and cardiogenic shock
• Describe contemporary antiplatelet treatment protocols in ST-elevation myocardial infarction (STEMI) and cardiogenic shock
• Discuss future antiplatelet and antithrombotic therapeutic targets

Intended Audience

Cardiologists

Commercial Supporter

This activity is supported by an unrestricted educational grant from Chiesi.

Max Credits

• 1.00 / AMA PRA Category 1 Credit
• 1.00 / ABIM MOC Point

Expires: May 30, 2023